Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
The medication also promotes weight loss, with patients losing ... The percentage may shock you. The drug can be used with or without CPAP treatment. While Zepbound alone showed significant ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback